Subject has a history of unexplained loss of consciousness or transient ischemic attack within 12 months of treatment start
loss of consciousness or transient ischemic attack within 12 months of randomization
History of seizure or any condition that may predispose to seizures at any time in the past. History of loss of consciousness or transient ischemic attack within 12 months of screening
History of loss of consciousness or transient ischemic attack within twelve (12) months of enrollment
History of loss of consciousness or transient ischemic attack within 12 months prior to enrollment
Any history of seizure; history of loss of consciousness or transient ischemic attack within 12 months of starting the study drug
Subject with a history of loss of consciousness or transient ischemic attack ? 12 months of study drug initiation.
For Cohort C: Has a history of loss of consciousness within 12 months of the screening visit
Subject has history of loss of consciousness or transient ischemic attack within 12 months prior to day 1.
The subject has a history of loss of consciousness, cerebrovascular accident, or transient ischemic attack within 12 months before the Day 1 visit.
Subject has a history of loss of consciousness or transient ischemic attack within 12 months before the Day 1 visit.
loss of consciousness or transient ischemic attack within 12 months of randomization
History of loss of consciousness or transient ischemic attack within 12 months prior to enrollment
unexplained loss of consciousness within the last 12 months,
For Arm D only: History of seizure, unexplained loss of consciousness, transient ischemic attack within 12 months of enrollment, cerebral vascular accident, and any brain metastases
History of loss of consciousness or transient ischemic attack within 12 months of enrollment
History of stroke or head injury associated with loss of consciousness within 12 months of registration
History of loss of consciousness or transient ischemic attack within past 12 months
History of stroke or transient ischemic attack
Subjects with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months
History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of AMG 757
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 3 months.
History of stroke or transient ischemic attack within the previous 6 months
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to Day 1
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to initiation of study treatment
History of stroke or transient ischemic attack within 6 months prior to registration
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 3 months Infection requiring intravenous antibiotics within 1 week of study enrollment (day 1)
History of stroke or transient ischemic attack within 6 months prior to day 1
History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of enrollment.
History of stroke or transient ischemic attack within 6 months of the randomization
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to Day 1
Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness).
Cerebrovascular disease manifested as prior stroke at any time or transient ischemic attack (TIA) in the 12 months prior to initiation of therapy
History of stroke or transient ischemic attack within 6 months prior to registration
History of stroke or transient ischemic attack within 3 months prior to cycle 1, day 1
History or presence of serious hemorrhage , hemoptysis or hematemesis within 3 months or a thromboembolic event (including Deep Vein Thrombosis (DVT), stroke and/or transient ischemic attack) within 6 months; Patients with squamous Non Small Cell Lung Cancer (NSCLC) should be excluded.
Cerebrovascular event (transient ischemic attack, stroke or CNS bleeding) within the last 12 months.
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attack within 6 months prior to day 1
History of transient ischemic attack (TIA) or stroke within 6 months of study entry
Stroke within 6 months of screening, or transient ischaemic attack (TIA) within 3 months of screening
215 History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of AMG 562.
History of transient ischemic attack within the previous 6 months
History of stroke or transient ischemic attack =< 6 months prior to registration
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within 6 months prior to Day1
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attacks within 6 months prior to study enrolment.
Patients are excluded if they have a history of stroke or transient ischemic attack within 6 months prior to randomization
History of stroke or transient ischemic attack within 6 months prior to cycle 1, day 1
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months prior to registration
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 6 months prior to beginning treatment.
History of stroke or transient ischemic attack, or other arterial thrombosis =< 12 months prior to randomization
Participants may not have had a history of a stroke or transient ischemic attack within six months
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
Patients must have not have a history of hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding 6 months that were not related to glioma surgery
Stroke or transient ischemic attack
Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment
History of a stroke or transient ischemic attack within 6 months
-  History of stroke or transient ischemic attack within 6 months prior to Day 1.
History of significant cerebrovascular disease (i.e. stroke or transient ischemic attack [TIA]) in the past 6 months or ongoing event with active symptoms or sequelae
History of stroke or transient ischemic attack within 6 months prior to day 1
Prior history of stroke or transient ischemic attack within 6 months prior to day -3
History of stroke or transient ischemic attack
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack (TIA) within 6 months prior to Cycle 1, Day 1
History of stroke or transient ischemic attack within 6 months prior to Day 1
Past history of stroke or transient ischemic attack requiring medical therapy
Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 3 months prior to registration
History of stroke or transient ischemic attack within 6 months prior to beginning treatment.
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attack within 6 months prior to day 1
History of stroke or transient ischemic attack within 3 months of first study dose
No history of stroke or transient ischemic attack
History of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to Day 1
History of progressive promyelocytic leukemia (PML), known history of pancreatitis, active grade 3 or higher viral, bacterial or fungal infection =< 2 weeks prior to registration and documented history of cerebrovascular event (stroke or transient ischemic attack [TIA]) =< 6 months prior to registration
Stroke or transient ischemic attack within 6 months of screening
History of stroke or transient ischemic attack in the preceding 6 months
History of stroke/transient ischemic attack
History of transient ischemic attack (TIA), cerebrovascular accident (CVA), gastrointestinal (GI) perforation or arterial thrombotic event within 6 months prior to randomization or symptomatic peripheral ischemia
Patients with a history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) within the past 6 months prior to study enrollment are NOT eligible for participation
Recent serious cardiovascular events (within 12 months) including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI).
History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism
Known active brain or central nervous system metastasis, or seizures requiring anticonvulsant treatment, cerebrovascular accident, or transient ischemic attack (< 6 months prior to enrollment)
Cerebral vascular accident (CVA) or transitory ischemic attack (TIA) in the year before enrollment, or presence of residual symptoms from CVA that happened more than a year before
Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to registration.
History of prior cerebrovascular event, (including transient ischemic attack) within 6 months of start of screening
Any history of cerebrovascular accident or transient ischemic attack
History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism (applicable to combination part only).
Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or Transient Ischemic Attack (TIA)
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of cerebrovascular accident, transient ischemic attack within 1 year prior to study enrollment
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHistory of cerebrovascular accident, transient ischemic attack within 1 year prior to study enrollment
Cerebrovascular accident or transient ischemic attack
Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose.
History of an ischemic insult in the previous 12 months (myocardial infarction, cerebral vascular accident, ischemic tissue from injury, transient ischemic attack)
History of seizures except for remote with specific etiology which has resolved (ex: alcohol induced seizure); transient ischemic attack (TIA) or cerebrovascular accident (CVA) within last 6 months
History of transient ischemic attack (TIA) or cerebrovascular accident (CVA)
Prior history of cerebrovascular accident or transient ischemic attack.
Cerebrovascular accident or transient ischemic attack
Patients must have international normalized ratio (INR) =< 1.2 within 14 days prior to registration; patients must not be receiving warfarin for therapeutic use, have history of cerebrovascular accident (CVA), history of transient ischemic attack (TIA) requiring intervention or treatment, pre-existing carotid artery disease requiring intervention or treatment, or current use of megestrol acetate (use within 10 days of registration)
History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA)/stroke or transient ischemic attack (TIA) or sub-arachnoid hemorrhage within =< 6 months prior to the first study treatment
Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months prior to the first date of study therapy.
Known active brain or central nervous system metastasis (less than 1 month out from definitive radiotherapy or surgery), or seizures requiring anticonvulsant treatment, or clinically significant cerebrovascular accident or transient ischemic attack (< 3 months)
Prior history of cerebrovascular accident or transient ischemic attack, or pre-existing carotid artery disease
Patients with a cerebrovascular accident or transient ischemic attack within the past six months
History of cerebrovascular attack or transient ischemic attack within 6 months prior to the initiation of therapy on this protocol
Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose
history of cerebrovascular accident (CVA) or transient ischemic attack (TIA),
Prior history of cerebrovascular accident or transient ischemic attack
History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA)/stroke or transient ischemic attack (TIA) or sub-arachnoid hemorrhage within =< 6 months prior to the first study treatment
History of cerebrovascular accident, including transient ischemic attack (TIA)
History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) =< 6 months prior to randomization
History of cerebrovascular accident including transient ischemic attack within the past 12 months
Patients with cerebrovascular accident or transient ischemic attack within 6 months of therapy are excluded
History of cerebrovascular accident or transient ischemic attack.
History of an ischemic insult in the previous 12 months (myocardial infarction, cerebral vascular accident, ischemic tissue from injury, transient ischemic attack.
History of cerebrovascular attack or transient ischemic attack within 6 months prior to the initiation of therapy on this protocol.
History of prior cerebrovascular accident (CVA), including transient ischemic attach (TIA)
Cerebrovascular accident or transient ischemic attack within 2 years
History of cerebrovascular accident within the past 6 months (e.g. transient ischemic attack [TIA])
History of dementia, Alzheimer’s disease, multi-infarct dementia or cerebrovascular accident (CVA) (history of transient ischemic attack [TIA] is allowed)
Cerebrovascular accident (CVA), transient ischemic attack (TIA) within the last 6 months prior to registration
History of cerebrovascular accident or transient ischemic attack within 3 months of first study dose
Uncontrolled active seizure disorder or history of cerebrovascular accident (CVA) or transient ischemic (TI) attack within the past 12 months
Cerebrovascular accident or transient ischemia.